Loading...

InVivo Therapeutics Holdings

Nasdaq:NVIV
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NVIV
Nasdaq
$6M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
  • InVivo Therapeutics Holdings has significant price volatility in the past 3 months.
NVIV Share Price and Events
7 Day Returns
-7.1%
NasdaqCM:NVIV
1.1%
US Medical Equipment
-1.2%
US Market
1 Year Returns
-68.5%
NasdaqCM:NVIV
15.1%
US Medical Equipment
3.4%
US Market
NVIV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
InVivo Therapeutics Holdings (NVIV) -7.1% -11% -55.8% -68.5% -99.6% -99.3%
US Medical Equipment 1.1% 1.4% 13.5% 15.1% 63.6% 103.7%
US Market -1.2% 1.2% 1.7% 3.4% 35.5% 41.6%
1 Year Return vs Industry and Market
  • NVIV underperformed the Medical Equipment industry which returned 15.1% over the past year.
  • NVIV underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
NVIV
Industry
5yr Volatility vs Market

Value

 Is InVivo Therapeutics Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for InVivo Therapeutics Holdings. This is due to cash flow or dividend data being unavailable. The share price is $0.65.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for InVivo Therapeutics Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are InVivo Therapeutics Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:NVIV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.06
NasdaqCM:NVIV Share Price ** NasdaqCM (2019-07-19) in USD $0.65
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 40.94x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of InVivo Therapeutics Holdings.

NasdaqCM:NVIV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NVIV Share Price ÷ EPS (both in USD)

= 0.65 ÷ -3.06

-0.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InVivo Therapeutics Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.
  • InVivo Therapeutics Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does InVivo Therapeutics Holdings's expected growth come at a high price?
Raw Data
NasdaqCM:NVIV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
70.4%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.38x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for InVivo Therapeutics Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on InVivo Therapeutics Holdings's assets?
Raw Data
NasdaqCM:NVIV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.45
NasdaqCM:NVIV Share Price * NasdaqCM (2019-07-19) in USD $0.65
United States of America Medical Equipment Industry PB Ratio Median Figure of 182 Publicly-Listed Medical Equipment Companies 4.37x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.79x
NasdaqCM:NVIV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NVIV Share Price ÷ Book Value per Share (both in USD)

= 0.65 ÷ 1.45

0.45x

* Primary Listing of InVivo Therapeutics Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InVivo Therapeutics Holdings is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess InVivo Therapeutics Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. InVivo Therapeutics Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is InVivo Therapeutics Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
70.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is InVivo Therapeutics Holdings expected to grow at an attractive rate?
  • InVivo Therapeutics Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • InVivo Therapeutics Holdings's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare InVivo Therapeutics Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:NVIV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:NVIV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 70.4%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.4%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:NVIV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:NVIV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 155 70 1
2022-12-31 34 7 1
2021-12-31 3 -8 1
2020-12-31 0 -13 1
2019-12-31 0 -12 1
NasdaqCM:NVIV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -12 -21
2018-12-31 -12 -23
2018-09-30 -13 -26
2018-06-30 -15 -32
2018-03-31 -17 -25
2017-12-31 -20 -27
2017-09-30 -20 -28
2017-06-30 -20 -24
2017-03-31 -19 -23
2016-12-31 -17 -23
2016-09-30 -18 -23
2016-06-30 -17 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • InVivo Therapeutics Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if InVivo Therapeutics Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:NVIV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from InVivo Therapeutics Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NVIV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.49 2.49 2.49 1.00
2022-12-31 0.28 0.28 0.28 1.00
2021-12-31 -0.44 -0.44 -0.44 1.00
2020-12-31 -0.93 -0.93 -0.93 1.00
2019-12-31 -1.13 -1.13 -1.13 1.00
NasdaqCM:NVIV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.06
2018-12-31 -4.69
2018-09-30 -8.41
2018-06-30 -21.64
2018-03-31 -18.55
2017-12-31 -20.29
2017-09-30 -21.23
2017-06-30 -19.00
2017-03-31 -18.13
2016-12-31 -18.89
2016-09-30 -19.03
2016-06-30 -16.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if InVivo Therapeutics Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess InVivo Therapeutics Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
InVivo Therapeutics Holdings has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has InVivo Therapeutics Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare InVivo Therapeutics Holdings's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • InVivo Therapeutics Holdings does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare InVivo Therapeutics Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare InVivo Therapeutics Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
InVivo Therapeutics Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from InVivo Therapeutics Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NVIV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -21.27 6.07 4.64
2018-12-31 -23.42 7.84 4.93
2018-09-30 -25.56 9.43 4.85
2018-06-30 -31.74 11.54 6.20
2018-03-31 -25.14 13.47 8.39
2017-12-31 -26.75 13.32 10.37
2017-09-30 -27.52 13.23 12.78
2017-06-30 -24.36 12.52 13.79
2017-03-31 -23.21 11.79 13.37
2016-12-31 -23.44 11.51 12.56
2016-09-30 -22.74 11.05 11.44
2016-06-30 -18.85 11.91 10.57
2016-03-31 -24.11 12.13 10.32
2015-12-31 -33.31 12.34 10.06
2015-09-30 -36.97 12.11 9.50
2015-06-30 -35.87 10.47 9.45
2015-03-31 -29.07 8.95 9.96
2014-12-31 -18.35 7.57 10.89
2014-09-30 -15.67 7.28 12.39
2014-06-30 -19.89 7.87 13.02
2014-03-31 -30.53 8.66 12.56
2013-12-31 -38.76 8.47 11.63
2013-09-30 -41.76 8.47 10.68
2013-06-30 -28.30 7.55 9.03
2013-03-31 -11.81 6.52 7.75
2012-12-31 4.66 6.40 6.38
2012-09-30 -21.77 5.89 4.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if InVivo Therapeutics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if InVivo Therapeutics Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if InVivo Therapeutics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess InVivo Therapeutics Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
InVivo Therapeutics Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is InVivo Therapeutics Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up InVivo Therapeutics Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • InVivo Therapeutics Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • InVivo Therapeutics Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of InVivo Therapeutics Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • InVivo Therapeutics Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from InVivo Therapeutics Holdings Company Filings, last reported 3 months ago.

NasdaqCM:NVIV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 13.54 0.00 13.20
2018-12-31 16.11 0.10 16.66
2018-09-30 18.48 0.22 19.71
2018-06-30 -1.91 0.33 22.32
2018-03-31 8.32 0.74 11.61
2017-12-31 10.11 0.85 12.91
2017-09-30 14.25 0.96 17.17
2017-06-30 18.97 1.07 21.85
2017-03-31 23.97 1.17 26.09
2016-12-31 28.95 1.28 33.04
2016-09-30 32.84 1.38 37.67
2016-06-30 37.61 1.48 41.63
2016-03-31 41.50 1.57 45.77
2015-12-31 16.93 1.67 20.19
2015-09-30 17.07 1.77 22.15
2015-06-30 15.31 1.86 25.11
2015-03-31 10.26 1.92 24.52
2014-12-31 5.92 1.94 13.46
2014-09-30 13.55 1.96 17.63
2014-06-30 14.02 1.98 20.85
2014-03-31 9.06 1.99 9.85
2013-12-31 12.89 2.01 13.98
2013-09-30 17.59 2.07 18.33
2013-06-30 22.34 1.92 22.23
2013-03-31 -14.33 1.80 10.30
2012-12-31 -2.31 1.58 12.83
2012-09-30 5.49 0.25 15.55
  • InVivo Therapeutics Holdings has no debt.
  • InVivo Therapeutics Holdings has no debt compared to 5 years ago when it was 21.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • InVivo Therapeutics Holdings has sufficient cash runway for 1.1 years based on current free cash flow.
  • InVivo Therapeutics Holdings has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -10.9% each year.
X
Financial health checks
We assess InVivo Therapeutics Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. InVivo Therapeutics Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is InVivo Therapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from InVivo Therapeutics Holdings dividends.
If you bought $2,000 of InVivo Therapeutics Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate InVivo Therapeutics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate InVivo Therapeutics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:NVIV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2016 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:NVIV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as InVivo Therapeutics Holdings has not reported any payouts.
  • Unable to verify if InVivo Therapeutics Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of InVivo Therapeutics Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as InVivo Therapeutics Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess InVivo Therapeutics Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can InVivo Therapeutics Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. InVivo Therapeutics Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of InVivo Therapeutics Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rich Toselli
COMPENSATION $741,948
AGE 61
TENURE AS CEO 1.6 years
CEO Bio

Dr. Richard M. Toselli, also known as Rich, M.D., has been serves as President, Chief Executive Officer and Director of InVivo Therapeutics Holdings Corp. (“InVivo”) since February 2, 2018 and has been its Chief Medical Officer since July 2017. Dr. Toselli served as Principal Financial Officer of InVivo Therapeutics Holdings Corp. from November 23, 2018 to 2019. Prior to being appointed President and Chief Executive Officer, Dr. Toselli served as InVivo’s Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as InVivo’s Chief Medical Officer. Before joining the Company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, since June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs — Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of Evidence-Based Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Dr. Toselli holds a bachelor of arts from Providence College, his medical degree from Brown University, and a masters of business administration from the UNC’s Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.

CEO Compensation
  • Rich's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rich's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the InVivo Therapeutics Holdings management team in years:

3.9
Average Tenure
66
Average Age
  • The tenure for the InVivo Therapeutics Holdings management team is about average.
Management Team

Rich Toselli

TITLE
President
COMPENSATION
$742K
AGE
61
TENURE
1.6 yrs

Bob Langer

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
70
TENURE
14.5 yrs

Joseph Vacanti

TITLE
Co-Founder
AGE
70
TENURE
14.5 yrs

Rich Christopher

TITLE
Chief Financial Officer
AGE
49
TENURE
0.5 yrs

Bill D'Agostino

TITLE
Senior Vice President of Operations
TENURE
5.1 yrs

Lou Vaickus

TITLE
Consultant
AGE
66
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the InVivo Therapeutics Holdings board of directors in years:

3.6
Average Tenure
65
Average Age
  • The tenure for the InVivo Therapeutics Holdings board of directors is about average.
Board of Directors

C. Merrifield

TITLE
Chair of the Board
COMPENSATION
$81K
AGE
68
TENURE
1.6 yrs

Rich Toselli

TITLE
President
COMPENSATION
$742K
AGE
61
TENURE
1.4 yrs

Bob Langer

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
70

Dan Marshak

TITLE
Director
COMPENSATION
$57K
AGE
62
TENURE
4.8 yrs

Christina Morrison

TITLE
Director
COMPENSATION
$60K
AGE
52
TENURE
3.1 yrs

V. Edgerton

TITLE
Member of Scientific Advisory Board

Rich Roberts

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$50K
AGE
75
TENURE
8.8 yrs

Jim Guest

TITLE
Member of Scientific Advisory Board
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess InVivo Therapeutics Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. InVivo Therapeutics Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What does InVivo Therapeutics Holdings Corp's (NASDAQ:NVIV) Balance Sheet Tell Us About Its Future?

Investors are always looking for growth in small-cap stocks like InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), with a market cap of US$2.97m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Company Info

Description

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Details
Name: InVivo Therapeutics Holdings Corp.
NVIV
Exchange: NasdaqCM
Founded: 2003
$6,052,358
9,311,320
Website: http://www.invivotherapeutics.com
Address: InVivo Therapeutics Holdings Corp.
One Kendall Square,
Floor 4,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NVIV Common Stock Nasdaq Capital Market US USD 28. Oct 2010
DB 04IB Common Stock Deutsche Boerse AG DE EUR 28. Oct 2010
Number of employees
Current staff
Staff numbers
6
InVivo Therapeutics Holdings employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/21 00:40
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/05/29
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.